玻璃体腔注射抗血管内皮生长因子单克隆抗体Bevacizumab的不良反应三例
被引量:3
摘要
抗血管内皮生长因子(VEGF)单克隆抗体Bevacizumab应用于眼科治疗脉络膜新生血管(CNV)、视网膜及虹膜新生血管均显示出良好疗效,但是其不良反应报告不多。我们从2007年7月开始使用Bevacizumab进行玻璃体腔注射,临床工作中遇到一些可能与药物有关的不良反应或是难以解释的现象,现报道如下。
出处
《中华眼底病杂志》
CAS
CSCD
北大核心
2008年第3期224-225,共2页
Chinese Journal of Ocular Fundus Diseases
参考文献4
-
1Rizzo S,Genovesi-Ebert F,Di Bartolo E,et al.Injection of intravitreal bevacizumab(Avastin)as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy(PDR).Graefes Arch Clin Exp Ophthalmol,2008,246:837-842. 被引量:1
-
2Chang LK,Sarraf D.Tears of the retinal pigment epithelium:an old problem in a new era.Retina,2007,523-534. 被引量:1
-
3Falkenstein IA,Cheng L,Freeman WR.Changes of intraocular pressure after intravitreal injection of bevacizumab (avastin).Retina,2007,27:044-1047. 被引量:1
-
4Hollands H,Wong J,Bruen R,et al.Short-term intraocular pressure changes after intravitreal of bevacizumab.Can J Ophthalmol,2007,42:807-811 被引量:1
同被引文献56
-
1Hurwitz H,Fehrenbacher L,Novotny W,et al.Bevacizumab plus irinotecan,fluorouracil and leucovorin for metastatic colorectalcancer[J].N Engl J Med,2004,350(23):2335-2342. 被引量:1
-
2Bhisitkul RB.Vascular endothelial growth factor biology:clinical implications for ocular treatments[J].Br J Ophthalmol,2006,90(12):1542-1547. 被引量:1
-
3Cheng CK,Peng PH,Tien LT,et al.Bevacizumab is not toxic to retinal ganglion cells after repeated intravitreal injection[J].Retina,2009,29(3):306-312. 被引量:1
-
4Brar VS,Sharma RK,Murthy RK,et al.Evaluation of differential toxicity of varying doses of bevacizumab on retinal ganglion cells,retinal pigment epithelial cells,and vascular endothelial growth fac-tor-enrirhed choroidal endothelial cells[J].J Ocul Pharmacol T-her,2009,25(6):507-511. 被引量:1
-
5Shahar J,Avery RL,Heilweil G,et at.Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizum-ab(Avastin)[J].Retina,2006,269(3):262-269. 被引量:1
-
6Manzano RP,Peyman GA,Khan P,et al.Testing intravitreal toxicity of bevacizumab(Avastin)[J].Retina,2006,26(3):257-261. 被引量:1
-
7Feiner L,Barr EE,Shui YB,et al.Safety of intravitreal injection of bevacizumab in rabbit eyes[J].Retina,2006,26(8):882-888. 被引量:1
-
8Luthra S,Narayanan R,Marques LE,et al.Evaluation of in vitro effects of bevaeizumab(Avastin) on retinal pigment epithelial,neu-rosensory retinal,and microvaseular endothelial cells[J].Retina,2006,26(5):512-518. 被引量:1
-
9Bakri SJ,Cameron JD,McCannel CA,et al.Absence of histologic retinal toxicity of intravitreal bevacizumabin a rabbit model[J].Am J Ophthalmol,2006,142(1):162-164. 被引量:1
-
10Spitzer MS,Wallenfels-Thilo B,Sierra A,et al.Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells[J].Br J Ophthalmo,2006,90(10):1316-1321. 被引量:1
引证文献3
-
1周丽琼,袁援生.Avastin眼内用药的安全性评价[J].医学综述,2010,16(10):1551-1553. 被引量:4
-
2胡六梅,徐鼎,汪浩,谢春蕾,高新蕊,王方.抗血管内皮生长因子单克隆抗体bevacizumab玻璃体腔单次注射后对侧眼缺血性视网膜病变一例[J].中华眼底病杂志,2012,28(5):528-529. 被引量:1
-
3徐雪姑,郁引飞,蔡永豪.眼科贝伐单抗和曲安奈德超说明书用药的风险评估[J].中国现代应用药学,2015,32(5):625-629. 被引量:3
二级引证文献8
-
1邱帅.玻璃体腔注射Avastin治疗老年性黄斑变性的手术配合体会[J].按摩与康复医学,2015,6(8):107-108.
-
2陈彦霓,陈子林.抗VEGF药物治疗新生血管性眼病的现状与展望[J].医学综述,2016,22(8):1550-1553. 被引量:10
-
3王哲.胰岛素强化治疗非增生期糖尿病视网膜病变对视网膜中谷氨酸表达的影响[J].检验医学与临床,2017,14(8):1098-1100. 被引量:5
-
4齐慧君.抗血管内皮生长因子疗法在眼科中的应用[J].中华眼科医学杂志(电子版),2017,7(2):49-59. 被引量:4
-
5宋学英,齐绍文,王浩,谢培培.脉络膜脱离型视网膜脱离术前玻璃体腔注射曲安奈德的临床疗效[J].国际眼科杂志,2017,17(10):1949-1951. 被引量:6
-
6吴兵,杨建,韦洪钧.贝伐珠单抗玻璃体腔内注射联合复合式小梁切除术治疗NVG的临床观察[J].国际眼科杂志,2018,18(7):1321-1323. 被引量:8
-
7张燕飞.眼科超说明书用药的现状与改进方案[J].中医药管理杂志,2019,27(12):220-222. 被引量:4
-
8何继武,段鹏,叶琳,樊伍峰,李素伟,程海军,张敏.超说明书用药的医学伦理分析——以眼科为例[J].医学与哲学,2021,42(24):17-20. 被引量:7